Security key
77313F106
ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT)
CUSIP: 77313F106
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 99,634,577
- Total 13F value
- $340,727,631
- Share change
- +2,510,957
- Put/Call ratio
- 7.5%
- SEC-reported price per share
- $3.42
- Number of holders
- 175
- Value change
- +$8,289,286
- Number of buys
- 85
- Number of sells
- 98
- Shares outstanding
- 109,299,832
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
175
Top holders
10
RCKT full security history
Ownership snapshot
Full 13F holder table
ROCKET PHARMACEUTICALS, INC. SEC filings
ROCKET PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD PORTFOLIO MANAGE...
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 5.4%
13D/G row: VANGUARD PORTFOLIO MANAGEMENT LLC
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD PORTFOLIO MANAGEMENT LLC leads the comparable SEC ownership view at 5.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD PORTFOLIO MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD PORTFOLIO MANAGEMENT LLC
5.4%
MAVERICK CAPITAL LTD
2.3%
WELLINGTON MANAGEMENT GROUP LLP
0.9%
Pedro P. Granadillo
0.05%
Elisabeth Bjork
0.05%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
Vanguard Portfolio Management · Company
|
5.4%
|
$24,501,197
5,847,541 shares
|
$0 | 30 Jun 2026 |
| MAVERICK CAPITAL LTD |
13F
13D/G
Company
|
2.3%
from 13D/G
|
$12,771,192
3,567,372 shares
|
— | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
0.9%
|
$7,895,181
1,004,476 shares
|
-$48,317,346 | 30 May 2025 |
| Pedro P. Granadillo |
3/4/5
Director
|
0.05%
|
$134,131
54,734 shares
|
— | 18 Jun 2025 |
| Elisabeth Bjork |
3/4/5
Director
|
0.05%
|
$172,000
50,000 shares
|
+$68,500 | 02 Jan 2026 |
| BlackRock, Inc. |
13F
Company
|
7.2%
|
$28,048,565
7,834,795 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
175
Shares
99,634,577
Rows available
175
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
197
Q2 2026 holders
175
Holder diff
-22
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|